The Boston Lung Cancer Survival Cohort
波士顿肺癌生存队列
基本信息
- 批准号:10603494
- 负责人:
- 金额:$ 123.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAir PollutionAlternative TherapiesArchivesAwardBiologicalBiological MarkersBostonCancer CenterCancer PatientCancer SurvivorCancer SurvivorshipCessation of lifeChest imagingClinicalCollaborationsCollectionCreativenessDNADana-Farber Cancer InstituteDataData Management ResourcesDatabasesDiagnosisDiagnosticDimensionsDisease ProgressionEducationElectronic Health RecordEnrollmentEnvironmentEnvironmental ExposureEpidemiologic MethodsEpidemiologyEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEpigenetic ProcessErlotinibEvaluationFundingGefitinibGeneral HospitalsGeneticGenomicsGrantHealthHealth InsuranceHeterogeneityHigh Resolution Computed TomographyImageImmune checkpoint inhibitorImmunotherapyIncomeIndividualInfrastructureInterdisciplinary StudyInternationalInvestigationLaboratoriesLeukocytesLibrariesLongterm Follow-upLungLung AdenocarcinomaMalignant NeoplasmsMalignant neoplasm of lungMassachusettsMeasuresMedical InformaticsMeteorologyMethodologyModelingMolecularMonitorMutationNatural HistoryNeighborhoodsNewly DiagnosedNon-Small-Cell Lung CarcinomaNucleic AcidsOccupationalOncogenicOutputPaperParticipantPathologyPatientsPeripheralPhenotypePlasmaPositron-Emission TomographyProductivityPrognostic MarkerPublishingPulmonary function testsQuality of lifeQuestionnairesRNAROS1 geneRaceRecording of previous eventsResearchResearch PersonnelResource SharingResourcesRisk FactorsSamplingSerumSmokingSocioeconomic StatusSourceSpecimenSurvivorsTherapeuticTissue BanksTissue MicroarrayTissue SurvivalTissuesTranslational ResearchTreatment outcomeTreatment-related toxicityTumor TissueU-Series Cooperative AgreementsUpdateUrineWorkX-Ray Computed Tomographyanticancer researchautomated image analysisbiobankbioinformatics infrastructurebuilt environmentcancer diagnosiscancer epidemiologycancer heterogeneitycancer survivalcancer therapyclinical investigationcohortcomorbiditydata managementdata repositorydietarydriver mutationeconomic determinanteffective therapyempowermentepidemiologic discoveriesfollow-upgenetic epidemiologygenotyped patientsimprovedincome insuranceindexinginnovationlung cancer screeningmethod developmentminority patientmortalitymultidisciplinarymutational statusnew technologynovelnovel therapeutic interventionnovel therapeuticsphenomephenomicspredictive markerprognosticprogramspulmonary functionracial disparityradiomicsrecruitrepositoryresponsesegregationsocial determinantssocioeconomicssurvival outcometargeted treatmenttraditional therapytranslational medicinetreatment disparitytreatment responsetreatment strategytumorvaping
项目摘要
The Boston Lung Cancer Survival (BLCS) cohort is a Cancer Epidemiology Cohort of more than 12,000 lung
cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute since 1992.
This rich resource enables research to understand lung cancer heterogeneity that has already identified
valuable prognostic markers and stimulated new treatment strategies. For example, the BLCS supported the
first discovery of the association between EGFR mutations and response to therapy with EGFR-tyrosine kinase
inhibitors and enabled research on effective treatments for non-small cell lung cancer patients with ALK and
ROS1 rearrangements. In 2017, the cohort evolved into a survivor epidemiology cohort that is sustained by a
U01 grant until May 2023. Our progress during the first U01 funding cycle (2017–2022) is substantial—we
have published over 100 papers, supported 6 new grants, and worked with 50 collaborators nationally and
internationally. With the U01 award expiring soon, there is an urgency to renew to: 1) maintain this first and
most comprehensive lung cancer survivor cohort with the longest follow-up period—an unmatched source of
data for translational research; 2) establish an innovative, detailed phenotyping database via automated image
analysis of high-resolution computed tomography, as well as a radiomics database; 3) enable the established
infrastructure to facilitate internal and external investigators to pilot methodologic approaches that will turn into
productive multidisciplinary project grants by focusing on survival and treatment toxicity; and 4) leverage the
Dana-Farber/Harvard Cancer Center Lung Program resources for creative multidisciplinary collaborations
focused on treatment outcomes. Renewed funding is also critical to recruit 2,500 new cases (for a total of
14,500 cases) to this already large cohort. New cases are vitally important to: 1) facilitate comparison of new
treatments and traditional therapy as well as evaluation of new clinical investigation in an ever-changing
therapeutic environment; 2) allow us to collect more cases with driver mutation data, as well as those treated
with immune checkpoint inhibitors; 3) promote collection of repeated biological samples to support developing
prognostic/predictive biomarkers; 4) allow us to collect detailed data enabling assessment of environmental
determinants as well as racial and socioeconomic determinants of survival; and 5) empower our studies to
identify radiomic, genomic, epigenetic, and other phenomic biomarkers, environmental determinants, and racial
and socioeconomic determinants that are relevant to patient survival to guide improved lung cancer screening
and treatment strategies. The BLCS is one of the largest lung cancer survival cohorts and encompasses a
wealth of biomarker, tumor molecular characterization, imaging, lung function, genetic, epigenetic, traditional
epidemiologic risk factor, and electronic health record data. With continued support, this comprehensive cohort
will provide unique opportunities to explore predictors of lung cancer survival and treatment outcomes,
catalyzing powerful translational research that improves the health of individuals with lung cancer.
波士顿肺癌生存(BLCS)队列是一个癌症流行病学队列,超过12,000名肺癌患者
项目成果
期刊论文数量(48)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non-Small Cell Lung Cancer.
非小细胞肺癌患者的诊断前戒烟和总体生存率。
- DOI:10.1001/jamanetworkopen.2023.11966
- 发表时间:2023-05-01
- 期刊:
- 影响因子:13.8
- 作者:Wang, Xinan;Romero-Gutierrez, Christopher W.;Kothari, Jui;Shafer, Andrea;Li, Yi;Christiani, David C.
- 通讯作者:Christiani, David C.
Automated temporalis muscle quantification and growth charts for children through adulthood.
成年后,儿童自动化的颞肌量化和生长图。
- DOI:10.1038/s41467-023-42501-1
- 发表时间:2023-11-09
- 期刊:
- 影响因子:16.6
- 作者:Zapaishchykova, Anna;Liu, Kevin X.;Saraf, Anurag;Ye, Zezhong;Catalano, Paul J.;Benitez, Viviana;Ravipati, Yashwanth;Jain, Arnav;Huang, Julia;Hayat, Hasaan;Likitlersuang, Jirapat;Vajapeyam, Sridhar;Chopra, Rishi B.;Familiar, Ariana M.;Nabavidazeh, Ali;Mak, Raymond H.;Resnick, Adam C.;Mueller, Sabine;Cooney, Tabitha M.;Haas-Kogan, Daphne A.;Poussaint, Tina Y.;Aerts, Hugo J. W. L.;Kann, Benjamin H.
- 通讯作者:Kann, Benjamin H.
Postdiagnosis BMI Change Is Associated with Non-Small Cell Lung Cancer Survival.
- DOI:10.1158/1055-9965.epi-21-0503
- 发表时间:2022-01
- 期刊:
- 影响因子:0
- 作者:Yuan Q;Du M;Loehrer E;Johnson BE;Gainor JF;Lanuti M;Li Y;Christiani DC
- 通讯作者:Christiani DC
Deep learning to estimate lung disease mortality from chest radiographs.
- DOI:10.1038/s41467-023-37758-5
- 发表时间:2023-05-16
- 期刊:
- 影响因子:16.6
- 作者:Weiss, Jakob;Raghu, Vineet K. K.;Bontempi, Dennis;Christiani, David C. C.;Mak, Raymond H. H.;Lu, Michael T. T.;Aerts, Hugo J. W. L.
- 通讯作者:Aerts, Hugo J. W. L.
Spirometry at diagnosis and overall survival in non-small cell lung cancer patients.
- DOI:10.1002/cam4.4808
- 发表时间:2022-12
- 期刊:
- 影响因子:4
- 作者:Zhai, Ting;Li, Yi;Brown, Robert;Lanuti, Michael;Gainor, Justin F.;Christiani, David C.
- 通讯作者:Christiani, David C.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David C Christiani其他文献
Blood Pressure at Age 3-24 years in a Rural Community in China ♦ 700
中国农村社区 3-24 岁人群血压状况♦700
- DOI:
10.1203/00006450-199804001-00721 - 发表时间:
1998-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Xiaobin Wang;Binyan Wang;Fangzhen Zhang;Changzhong Chen;Jianhua Yang;Zhian Fang;Xiaobin Zhang;David C Christiani;Scott T Weiss;Barry Zuckerman;Xiping Xu - 通讯作者:
Xiping Xu
David C Christiani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David C Christiani', 18)}}的其他基金
Harvard TH Chan Education and Research Center for Occupational Safety and Health
哈佛陈曾熙职业安全与健康教育研究中心
- 批准号:
10762715 - 财政年份:2023
- 资助金额:
$ 123.12万 - 项目类别:
OCCUPATIONAL SAFETY AND HEALTH EDUCATION AND RESEARCH CENTERS (T42)
职业安全健康教育研究中心(T42)
- 批准号:
10456000 - 财政年份:2018
- 资助金额:
$ 123.12万 - 项目类别:
Multi-Pathway DNA Repair Capacity Measurements in Lung Cancer Patients and Healthy Controls
肺癌患者和健康对照组的多途径 DNA 修复能力测量
- 批准号:
10447766 - 财政年份:2018
- 资助金额:
$ 123.12万 - 项目类别:
OCCUPATIONAL SAFETY AND HEALTH EDUCATION AND RESEARCH CENTERS (T42)
职业安全健康教育研究中心(T42)
- 批准号:
10249049 - 财政年份:2018
- 资助金额:
$ 123.12万 - 项目类别:
OCCUPATIONAL SAFETY AND HEALTH EDUCATION AND RESEARCH CENTERS (T42)
职业安全健康教育研究中心(T42)
- 批准号:
9794128 - 财政年份:2018
- 资助金额:
$ 123.12万 - 项目类别:
Multi-Pathway DNA Repair Capacity Measurements in Lung Cancer Patients and Healthy Controls
肺癌患者和健康对照组的多途径 DNA 修复能力测量
- 批准号:
10228767 - 财政年份:2018
- 资助金额:
$ 123.12万 - 项目类别:
Research Training in Pulmonary Immunology and Allergy at MGH
MGH 肺部免疫学和过敏研究培训
- 批准号:
10202695 - 财政年份:2013
- 资助金额:
$ 123.12万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 123.12万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 123.12万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 123.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 123.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 123.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




